Marvel Biosciences Corp is a life sciences company focused on the discovery and development of a synthetic derivative compound of a known drug... Show more
The Stochastic Oscillator for MBCOF moved out of overbought territory on July 16, 2025. This could be a bearish sign for the stock and investors may want to consider selling or taking a defensive position. A.I.dvisor looked at 24 similar instances where the indicator exited the overbought zone. In of the 24 cases the stock moved lower. This puts the odds of a downward move at .
The 10-day RSI Indicator for MBCOF moved out of overbought territory on July 17, 2025. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 12 similar instances where the indicator moved out of overbought territory. In of the 12 cases, the stock moved lower in the following days. This puts the odds of a move lower at .
The Moving Average Convergence Divergence Histogram (MACD) for MBCOF turned negative on July 17, 2025. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 15 similar instances when the indicator turned negative. In of the 15 cases the stock turned lower in the days that followed. This puts the odds of success at .
MBCOF broke above its upper Bollinger Band on July 11, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Following a +1 3-day Advance, the price is estimated to grow further. Considering data from situations where MBCOF advanced for three days, in of 6 cases, the price rose further within the following month. The odds of a continued upward trend are .
The Aroon Indicator entered an Uptrend today. In of 43 cases where MBCOF Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.000) is normal, around the industry mean (18.130). P/E Ratio (0.000) is within average values for comparable stocks, (58.963). MBCOF's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (2.526). Dividend Yield (0.000) settles around the average of (0.041) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (271.880).
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. MBCOF’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. MBCOF’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.
Industry Biotechnology
A.I.dvisor tells us that MBCOF and XENE have been poorly correlated (+20% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that MBCOF and XENE's prices will move in lockstep.
Ticker / NAME | Correlation To MBCOF | 1D Price Change % | ||
---|---|---|---|---|
MBCOF | 100% | -6.75% | ||
XENE - MBCOF | 20% Poorly correlated | +1.58% | ||
BSFAF - MBCOF | 8% Poorly correlated | N/A | ||
ZEOX - MBCOF | 6% Poorly correlated | +5.79% | ||
ATYR - MBCOF | 5% Poorly correlated | -0.86% | ||
LENZ - MBCOF | 3% Poorly correlated | -1.76% | ||
More |